Welcome to our dedicated page for Icosavax news (Ticker: ICVX), a resource for investors and traders seeking the latest updates and insights on Icosavax stock.
Icosavax, Inc. (NASDAQ: ICVX) is a Seattle-based biopharmaceutical company committed to developing safe and effective vaccines targeting infectious diseases with significant unmet medical needs. Founded in 2017, the company harnesses breakthrough computationally-designed virus-like particle (VLP) technology, exclusively licensed from the Institute for Protein Design at the University of Washington.
Icosavax’s lead vaccine candidate, IVX-A12, is currently in Phase 2 clinical trials and targets respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), aiming to deliver a first-in-class bivalent combination vaccine for older adults. Recent trial data indicates promising immune responses post-revaccination with their component IVX-121, suggesting potential for durable protection and differentiation in the RSV vaccine market.
The company's VLP platform is designed to enable the multivalent, particle-based display of complex viral antigens, aiming to induce broad, robust, and durable immune responses. This innovative technology is also being leveraged to develop vaccines targeting other critical pathogens, including influenza and SARS-CoV-2.
Icosavax is actively engaged in various stages of clinical trials and expects to announce topline interim data for the IVX-A12 Phase 2 trial by the end of 2023. The company continues to advance its pipeline with a vision of creating combination and pan-respiratory vaccines to address life-threatening respiratory diseases while aiming to reduce healthcare costs.
In addition to its promising vaccine candidates, Icosavax has established important partnerships and relies on third-party collaborations for manufacturing, research, and clinical testing. The company is navigating regulatory landscapes in the U.S. and internationally to bring its innovative solutions to market.
For further information, visit the Icosavax website.
Icosavax has released interim data from its Phase 1/2 trial of IVX-411, a vaccine candidate targeting SARS-CoV-2. The immunogenic response was below expectations in both naïve and previously vaccinated subjects, although overall safety and tolerability were favorable. The trial involved 168 adults with varying doses and included a focus on neutralizing efficacy against the Omicron variant. Despite the initial results, the company continues to investigate potential discrepancies and remains on track for contributing data on another candidate, IVX-121, by Q2 2022.
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical firm, announced its participation in the Cowen 42nd Annual Health Care Conference, scheduled for March 7-9, 2022. Adam Simpson, CEO, will join an Infectious Disease corporate panel on March 9 at 10:30 a.m. Eastern Time. Interested parties can access the live audio webcast via the Investor Relations section of the Icosavax website, with replays available for 30 days post-event.
The company focuses on innovative virus-like particle technology for vaccine development against respiratory diseases, including candidates targeting RSV, hMPV, and SARS-CoV-2.
Icosavax (Nasdaq: ICVX) announced a corporate update on January 7, 2022, highlighting its innovative virus-like particle (VLP) platform for developing vaccines. Key milestones include exercising a patent license for an influenza vaccine and ongoing Phase 1 trials for its IVX-121 and IVX-411 candidates targeting RSV and SARS-CoV-2, respectively. The company appointed notable experts to its Scientific Advisory Board and Board of Directors, expanded its Seattle headquarters, and reported a preliminary cash position of $281 million, projected to support operations through 2024.
Icosavax, Inc. (Nasdaq: ICVX) has appointed John Shiver, Ph.D., to its Board of Directors. With over 30 years in vaccine research, his experience includes significant roles at Sanofi Pasteur and Merck. He has contributed to the licensure of 14 pharmaceutical products and aims to leverage Icosavax’s innovative virus-like particle (VLP) platform technology for developing vaccines against infectious diseases like RSV and SARS-CoV-2. CEO Adam Simpson emphasizes Dr. Shiver's expertise as integral to advancing the company’s mission during this critical growth phase.
Icosavax, a biopharmaceutical company focused on vaccines for infectious diseases, reported its third-quarter financial results for 2021. Key highlights include the initiation of a Phase 1/1b trial for IVX-121, targeting Respiratory Syncytial Virus, and progression of the IVX-411 Phase 1/2 trial for SARS-CoV-2. The company completed a successful IPO, raising $209.3 million. Financially, Icosavax reported a net loss of $34.4 million, with cash reserves of $293.9 million, projected to last through 2024. Significant increases in R&D and G&A expenses were noted, primarily due to stock-based compensation adjustments.
Icosavax, a biopharmaceutical company focusing on vaccine development, announced participation in two investor conferences. Adam Simpson, CEO, will join the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 AM ET, and the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 4:20 PM ET. Webcasts for both events will be available on Icosavax's Investor Relations site and accessible for 30 days. The company specializes in vaccines for respiratory diseases using its innovative virus-like particle platform technology.
Icosavax, Inc. (Nasdaq: ICVX) has initiated two clinical trials for its vaccine candidates, IVX-121 for Respiratory Syncytial Virus (RSV) and IVX-411 for SARS-CoV-2. The company raised $209.3 million from its IPO in July, which will fund operations through at least 2024. For Q2 2021, Icosavax reported a net loss of $8.6 million and increased R&D expenses due to clinical development efforts. As of June 30, 2021, cash reserves stood at $111.8 million, significantly up from $15.5 million at the end of 2020, indicating strong liquidity for ongoing projects.
Icosavax, Inc. (NASDAQ: ICVX) has appointed Elizabeth Bekiroğlu as General Counsel. With over 15 years of experience in biotechnology legal matters, Bekiroğlu previously served as Associate General Counsel at Seagen, where she supported the company’s growth into a multinational entity. CEO Adam Simpson expressed enthusiasm for Bekiroğlu's insights as Icosavax progresses its clinical candidates. The company focuses on developing vaccines against infectious diseases using its virus-like particle technology, targeting viruses such as RSV, hMPV, and SARS-CoV-2.
Icosavax announces the initiation of a Phase 1/1b clinical trial for IVX-121, a vaccine targeting Respiratory Syncytial Virus (RSV), aimed at healthy and older adults. The trial will evaluate the vaccine's safety and immunogenicity across three dose levels. The company plans future trials for a combination vaccine targeting both RSV and human Metapneumovirus (hMPV), with an IND submission to the FDA expected in early 2022. The trial includes up to 90 healthy adults and 217 older adults, assessing long-term immune response.
Icosavax, Inc. (Nasdaq: ICVX) announced the unexpected passing of co-founder and Chairman, Dr. Tadataka Yamada, on August 4, 2021. His legacy is noted for his extensive contributions to public health and the life sciences, including leadership roles at Takeda, GlaxoSmithKline, and the Gates Foundation. CEO Adam Simpson emphasized Dr. Yamada's dedication and the company's commitment to advancing vaccine candidates for respiratory diseases, such as RSV and SARS-CoV-2, as envisioned by him. Icosavax leverages its virus-like particle platform technology to develop vaccines.
FAQ
What is the market cap of Icosavax (ICVX)?
What does Icosavax, Inc. specialize in?
Where is Icosavax, Inc. located?
What is the focus of Icosavax's lead vaccine candidate IVX-A12?
What technology does Icosavax use for its vaccines?
What recent achievement has Icosavax made in its clinical trials?
When is Icosavax expected to announce the topline interim data for IVX-A12?
What other diseases is Icosavax targeting with its vaccine pipeline?
What is the underlying goal of Icosavax’s vaccine development?
Who are the key contacts for media and investor relations at Icosavax?
Where can I find more information about Icosavax?
